Charles River rises on 2026 forecast update, long-term targets

Charles River Laboratories International

24/09/2026 15:50

** Shares of contract drug developer Charles River Laboratories CRL.N rise 6.1% to $294.16
** Co expects 2026 organic revenue growth and adjusted EPS at the upper ends of its previous forecasts of 0% to 1% and $11.15 to $11.45, respectively, citing continued favorable demand from biotech and pharma clients
** Targets annual organic revenue growth of 5% to 7% and low-double-digit growth in adjusted EPS from 2027 through 2030
** Expects adjusted operating margin to rise to about 24% by 2030 from a forecast of 21% to 21.3% in 2026
** CRL plans to save more than $300 million between 2027 and 2030 by simplifying operations and increasing the use of automation and digital tools
** Evercore ISI says the 5% to 7% revenue growth target is above expectations and "highly achievable" under normal market conditions, but the 2030 margin target could "raise a few eyebrows" despite the $300 mln savings plan
** Including session's move, CRL up 47.7% YTD 

 (Reporting by Kunal Das in Bengaluru)
 ((Kunal.Das2@thomsonreuters.com;))